Aric Hall, MD
Hematology & Oncology · Madison, WINPI 1538332804
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,373 of the $1,596 with a category attached, or 86.1%. Every reported general payment came from a single manufacturer, National Marrow Donor Program.
Across 4 payments — averaging $398.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$2K
Across 42 payments — averaging $11,770 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$350K
- Sanofi US Services Inc.$65K
- Syndax Pharmaceuticals, Inc.$29K
- National Marrow Donor Program$26K
- Ichnos Glenmark Innovation Inc$24K
What the payments were for
- Travel & lodging$1,37386%
- Food & beverage$22214%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 4 | $1,596 |
How this compares
$1,596 in reported general payments places this provider in the 65th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 77 | $1,286,789 |
| Lenalidomide | 53 | $653,676 |
| RevlimidLenalidomide | 35 | $602,373 |
| PomalystPomalidomide | 21 | $466,522 |
| PromactaEltrombopag Olamine | 12 | $458,899 |
| VenclextaVenetoclax | 24 | $185,826 |
| CresembaIsavuconazonium Sulfate | 11 | $66,916 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $38,331 |
| EliquisApixaban | 37 | $21,794 |
| Imatinib Mesylate | 24 | $16,493 |
| Posaconazole | 11 | $15,260 |
| XareltoRivaroxaban | 18 | $10,755 |
| Acyclovir | 472 | $7,779 |
| OxycontinOxycodone Hcl | 14 | $6,570 |
| Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf | 15 | $2,597 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Madison
- Vincent MaMadison$37K
- Priyanka PophaliMadison$32K
- Hamid EmamekhooMadison$23K
- Elisavet PaplomataMadison$21K
- Timothy SchmidtMadison$19K
- Sima Ehsani ChimehMadison$17K
- Kalyan Vara Ganesh NadimintiMadison$17K
- Christos KyriakopoulosMadison$16K
- Matthew BrunnerMadison$15K
- Lyndsey RunaasMadison$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.